Validation & Dissemination of Polyherbal formulation for Management of Hypertension

IOE, BH0 个研究点目标入组 0 人开始时间: 待定最近更新: 2023年5月29日

研究概览

暂无简介。

•1.Patients willing to participate in the study.
•2.Patients of either sex with ages between 18-60 years.
•3.Patients having Hypertension between the time intervals of 6 months to 1 year.
•4.Patients suffering from Stage I Hypertension (Systolic Blood Pressure 140-159mm of Hg, Diastolic Blood Pressure 90-99mm of Hg)
•5.Patients suffering from Stage I Hypertension are those who are on allopathic medicines.
•6.Patients suffering from Isolated Systolic Hypertension.

•1.Patients not willing to participate in the study.
•2.Patients of either sex below 18 years & above 60 years will be excluded from the study.
•3.Patients having Hypertension for <6 months and >1 year will be excluded.
•4.Patients of Stage II Hypertension (Systolic Blood Pressure >160mmHg and Diastolic Blood Pressure >100mmHg)
•5.Patients suffering from serious comorbidities like renal failure, coronary artery disease, Type 2 Diabetes Mellitus, cervical spondylosis, taking medications/drugs (oral contraceptives, steroids, chronic use of NSAIDs etc.).
•6.Alcoholics and/or drug abusers.
•7.History of hypersensitivity to the trial drug or any of its ingredients.
•8.Pregnant/ lactating woman.
•9.Patients who have completed participation in any other clinical trial during the past 6 months.

发起方

IOE, BH